A review of hepatitis B management in pre- and post-liver transplant recipients

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Liver transplantation was approved for treatment of decompensated cirrhosis in the United States in 1983. Hepatitis B and hepatitis C viruses are the leading causes of liver transplantation for viral hepatitis and hepatitis B is also an important cause of liver transplantation for called acute liver failure) due to either acute hepatitis B or an acute exacerbation of chronic hepatitis B. However, until the introduction of hepatitis B immunoglobulin and nucleoside/nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal recurrence with a dismal prognosis. The widespread use of oral anti-virals in the US has led to a decreased incidence of decompensated liver disease and patients waitlisted for liver transplantation. Among patients listed for hepatocellular carcinoma, the decrease in waitlist registration was also least dramatic among patients with HBV, possibly related to the use of oral antivirals. At present, liver transplantation for hepatitis B, regardless of whether for decompensated cirrhosis, hepatocellular carcinoma satisfying Milan criteria or acute liver failure has excellent outcomes with results comparable if not better to other liver transplant recipients. This article will review the management of patients with decompensated cirrhosis from HBV prior to liver transplantation, the use of hepatitis B positive donors and the prevention and management of hepatitis B after liver transplantation.

Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalOpen Immunology Journal
Volume3
Issue number1
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Hepatitis B
Liver Transplantation
Liver
Fibrosis
Acute Liver Failure
Hepatocellular Carcinoma
Transplant Recipients
Chronic Hepatitis B
Nucleosides
Hepacivirus
Hepatitis
Antiviral Agents
Immunoglobulins
Liver Diseases
Nucleotides
Tissue Donors
Recurrence
Incidence

All Science Journal Classification (ASJC) codes

  • Immunology
  • Immunology and Allergy

Cite this

A review of hepatitis B management in pre- and post-liver transplant recipients. / Mukherjee, Sandeep.

In: Open Immunology Journal, Vol. 3, No. 1, 2010, p. 27-35.

Research output: Contribution to journalReview article

@article{c0ecc3f5b3824cc7b8aca69a04c5e93c,
title = "A review of hepatitis B management in pre- and post-liver transplant recipients",
abstract = "Liver transplantation was approved for treatment of decompensated cirrhosis in the United States in 1983. Hepatitis B and hepatitis C viruses are the leading causes of liver transplantation for viral hepatitis and hepatitis B is also an important cause of liver transplantation for called acute liver failure) due to either acute hepatitis B or an acute exacerbation of chronic hepatitis B. However, until the introduction of hepatitis B immunoglobulin and nucleoside/nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal recurrence with a dismal prognosis. The widespread use of oral anti-virals in the US has led to a decreased incidence of decompensated liver disease and patients waitlisted for liver transplantation. Among patients listed for hepatocellular carcinoma, the decrease in waitlist registration was also least dramatic among patients with HBV, possibly related to the use of oral antivirals. At present, liver transplantation for hepatitis B, regardless of whether for decompensated cirrhosis, hepatocellular carcinoma satisfying Milan criteria or acute liver failure has excellent outcomes with results comparable if not better to other liver transplant recipients. This article will review the management of patients with decompensated cirrhosis from HBV prior to liver transplantation, the use of hepatitis B positive donors and the prevention and management of hepatitis B after liver transplantation.",
author = "Sandeep Mukherjee",
year = "2010",
doi = "10.2174/1874226201003010027",
language = "English",
volume = "3",
pages = "27--35",
journal = "Open Immunology Journal",
issn = "1874-2262",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - A review of hepatitis B management in pre- and post-liver transplant recipients

AU - Mukherjee, Sandeep

PY - 2010

Y1 - 2010

N2 - Liver transplantation was approved for treatment of decompensated cirrhosis in the United States in 1983. Hepatitis B and hepatitis C viruses are the leading causes of liver transplantation for viral hepatitis and hepatitis B is also an important cause of liver transplantation for called acute liver failure) due to either acute hepatitis B or an acute exacerbation of chronic hepatitis B. However, until the introduction of hepatitis B immunoglobulin and nucleoside/nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal recurrence with a dismal prognosis. The widespread use of oral anti-virals in the US has led to a decreased incidence of decompensated liver disease and patients waitlisted for liver transplantation. Among patients listed for hepatocellular carcinoma, the decrease in waitlist registration was also least dramatic among patients with HBV, possibly related to the use of oral antivirals. At present, liver transplantation for hepatitis B, regardless of whether for decompensated cirrhosis, hepatocellular carcinoma satisfying Milan criteria or acute liver failure has excellent outcomes with results comparable if not better to other liver transplant recipients. This article will review the management of patients with decompensated cirrhosis from HBV prior to liver transplantation, the use of hepatitis B positive donors and the prevention and management of hepatitis B after liver transplantation.

AB - Liver transplantation was approved for treatment of decompensated cirrhosis in the United States in 1983. Hepatitis B and hepatitis C viruses are the leading causes of liver transplantation for viral hepatitis and hepatitis B is also an important cause of liver transplantation for called acute liver failure) due to either acute hepatitis B or an acute exacerbation of chronic hepatitis B. However, until the introduction of hepatitis B immunoglobulin and nucleoside/nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal recurrence with a dismal prognosis. The widespread use of oral anti-virals in the US has led to a decreased incidence of decompensated liver disease and patients waitlisted for liver transplantation. Among patients listed for hepatocellular carcinoma, the decrease in waitlist registration was also least dramatic among patients with HBV, possibly related to the use of oral antivirals. At present, liver transplantation for hepatitis B, regardless of whether for decompensated cirrhosis, hepatocellular carcinoma satisfying Milan criteria or acute liver failure has excellent outcomes with results comparable if not better to other liver transplant recipients. This article will review the management of patients with decompensated cirrhosis from HBV prior to liver transplantation, the use of hepatitis B positive donors and the prevention and management of hepatitis B after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=78249267264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249267264&partnerID=8YFLogxK

U2 - 10.2174/1874226201003010027

DO - 10.2174/1874226201003010027

M3 - Review article

AN - SCOPUS:78249267264

VL - 3

SP - 27

EP - 35

JO - Open Immunology Journal

JF - Open Immunology Journal

SN - 1874-2262

IS - 1

ER -